Bergen, 25 October 2006: NorDiag ASA (NORD) reported revenue of NOK 1.2 million for the third quarter 2006, compared with NOK 1.4 million in the previous quarter and NOK 1.9 million in the same period in 2005. For the first nine months of 2006, revenue was NOK 4.5 million (3.9). During the quarter, NorDiag made significant progress in establishing its Genefec™ test for diagnosis of colorectal cancer in international markets, and in October secured key IP rights to broaden the product portfolio for cancer screening.

The revenue of NOK 1.2 million in the third quarter almost exclusively represents sales in Norway. The revenue decline relates to difficulties in the sample preparation process in the laboratory. The company is working to implement new process technologies which will increase the automation and scalability for higher volumes and enable technology transfer to other labs. The operating loss for the third quarter was NOK -7.5 million, compared to NOK -7.7 in the previous quarter and NOK -3.6 million in the third quarter 2005.

NorDiag signed important new agreements in the quarter, including a Letter of Intent with the world’s largest diagnostics company - Quest Diagnostics - for introduction of Genefec™ in the UK market, and an agreement with India’s largest healthcare provider Manipal Acunova for introduction of Genefec™ in India. NorDiag expects initial product launches in these markets towards the end of the year.

After the end of the quarter, NorDiag has secured worldwide, exclusive commercial rights for a new DNA analysis method. The technology is currently being validated in a clinical trial study, and NorDiag expects to develop a test for first-line screening for colorectal cancer for launch already in 2007. The new screening test will complement NorDiag’s more advanced Genefec™ test, which is being marketed as a diagnostic colorectal cancer test and a second-line test for colorectal cancer screening programs.

For further information, please see www.nordiag.no or contact;
CEO Christian Horn in NorDiag ASA, tel: +47 901 63 153

About NorDiag ASA:
NorDiag is a biotechnology company focusing on early diagnosis of cancer. The company’s first product is Genefec™ for genetic diagnosis of colorectal cancer. The Genefec assay is a non-invasive test using faecal samples as specimen. The test is highly specific, easy to automate and currently used and reimbursed as a diagnostic assay in Scandinavia. The company also has R&D programmes for new technologies and products within colorectal cancer, lung cancer and pancreatic cancer. NorDiag is listed on Oslo Stock Exchange under the ticker NORD